Daily administration of liraglutide at 3 mg for 32 weeks significantly improves insulin sensitivity in obese women with polycystic ovary syndrome, as demonstrated by reductions in fasting blood glucose and HOMA-IR, independent of weight loss.

Liraglutide activates receptors in the pancreas that make insulin cells release less insulin when blood sugar is high, which lowers excess insulin in the blood. This drop in insulin reduces fat buildup around the organs and calms down inflammation in fat tissue. With less inflammation, muscle, liver, and fat cells respond better to insulin, so they take up more sugar from the blood and the liver stops making too much sugar.